Vilobelimab Biosimilar - Research Grade

Human

C5

5mg/ml

Human IgG4 - kappa

CHO Cells

https://www.imgt.org/mAb-DB/

ICH3002

P01031

Blue ice

Complement component C5 lies at the heart of terminal complement activation, driving the inflammatory anaphylatoxin C5a and membrane attack complex formation. This anti-human C5 recombinant monoclonal antibody is supplied as an unconjugated, non-therapeutic analog of vilobelimab for research use only. Produced to stringent in vivo standards with low endotoxin, it is manufactured in scalable milligram (mg) to gram (g) quantities to serve high-throughput and bulk laboratories. The reagent is well suited to complement inhibition assays, in vitro functional screening, and in vivo models of complement-mediated disease, providing dependable, lot-consistent results.

REGN3918,REGN-3918,complement 5, C5a anaphylatoxin

Detects human C5

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

4 weeks